T
Teresa Ward
Researcher at Peter MacCallum Cancer Centre
Publications - 10
Citations - 1840
Teresa Ward is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Targeted therapy & Kinase. The author has an hindex of 6, co-authored 9 publications receiving 1643 citations. Previous affiliations of Teresa Ward include Walter and Eliza Hall Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim,Elgene Lim,François Vaillant,Di Wu,Di Wu,Natasha C. Forrest,Bhupinder Pal,Adam H. Hart,Marie Liesse Asselin-Labat,David E. Gyorki,David E. Gyorki,Teresa Ward,Audrey Partanen,Frank Feleppa,Lily I. Huschtscha,Heather Thorne,Stephen B. Fox,Max Yan,Juliet D. French,Melissa A. Brown,Gordon K. Smyth,Jane E. Visvader,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Geoffrey J. Lindeman +24 more
TL;DR: It is found that breast tissue from BRCA1 mutation carriers harbors an expanded luminal progenitor population that shows factor-independent growth in vitro, and the findings suggest that an aberrant luminalprogenitor population is a target for transformation in BRCa1-associated basal tumors.
Journal ArticleDOI
Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes,François Vaillant,Elgene Lim,Lily Lee,Kelsey Breslin,Frank Feleppa,Siddhartha Deb,Matthew E. Ritchie,Elena A Takano,Teresa Ward,Stephen B. Fox,Daniele Generali,Gordon K. Smyth,Andreas Strasser,David C.S. Huang,Jane E. Visvader,Geoffrey J. Lindeman +16 more
TL;DR: In vivo evidence is provided that BH3 mimetics can be used to sensitize primary breast tumors to chemotherapy and further suggest that elevated BCL-2 expression constitutes a predictive response marker in breast cancer.
Journal ArticleDOI
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Rachel Ramsdale,Robert N. Jorissen,Robert N. Jorissen,Frederic Zhentao Li,Frederic Zhentao Li,Sheren Al-Obaidi,Teresa Ward,Karen E. Sheppard,Karen E. Sheppard,Patricia Bukczynska,Richard J. Young,Samantha E. Boyle,Samantha E. Boyle,Mark Shackleton,Gideon Bollag,Georgina V. Long,Eugene Tulchinsky,Helen Rizos,Helen Rizos,Richard B. Pearson,Grant A. McArthur,Amardeep S. Dhillon,Amardeep S. Dhillon,Petranel T. Ferrao +23 more
TL;DR: Gene expression data from a panel of melanoma cell lines and a patient cohort showed that JUN expression correlated with a mesenchymal gene signature, implicating c-JUN as a key mediator of the mesenchyal-like phenotype associated with drug resistance.
Journal ArticleDOI
Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14
Marie Liesse Asselin-Labat,Kate D. Sutherland,François Vaillant,François Vaillant,David E. Gyorki,David E. Gyorki,Di Wu,Di Wu,Sheridan L Holroyd,Kelsey Breslin,Teresa Ward,Wei Shi,Wei Shi,Mary L. Bath,Siddhartha Deb,Stephen B. Fox,Gordon K. Smyth,Gordon K. Smyth,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Jane E. Visvader,Jane E. Visvader +22 more
TL;DR: These studies identify GATA-3 as an important regulator of tumor initiation through its ability to promote the differentiation of committed luminal progenitor cells.
Journal ArticleDOI
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Shatha AbuHammad,Carleen Cullinane,Carleen Cullinane,Claire Martin,Zoe Bacolas,Teresa Ward,Huiqin Chen,Alison Slater,Kerry Ardley,Laura Kirby,Keefe T. Chan,Keefe T. Chan,Natalie Brajanovski,Lorey K. Smith,Lorey K. Smith,Aparna D. Rao,Emily J. Lelliott,Emily J. Lelliott,Margarete Kleinschmidt,Ismael A. Vergara,Ismael A. Vergara,Anthony T. Papenfuss,Anthony T. Papenfuss,Anthony T. Papenfuss,Peter Lau,Peter Lau,Prerana Ghosh,Sue Haupt,Sue Haupt,Ygal Haupt,Ygal Haupt,Ygal Haupt,Elaine Sanij,Elaine Sanij,Gretchen Poortinga,Gretchen Poortinga,Richard B. Pearson,Richard B. Pearson,Richard B. Pearson,Hendrik Falk,David J. Curtis,Stupple Paul Anthony,Mark G. Devlin,Ian P. Street,Ian P. Street,Michael A. Davies,Grant A. McArthur,Grant A. McArthur,Karen E. Sheppard,Karen E. Sheppard +49 more
TL;DR: It is established that palbociclib inhibition of the PRMT5–MDM4 axis is essential for robust melanoma cell sensitivity and preclinical evidence that coinhibition of CDK4/6 andPRMT5 is an effective and well-tolerated therapeutic strategy is provided.